Biosafety Rules Tied to Gene Therapy Put Heavy Financial Burden on Hospitals: Expert

Yoshikazu Yonemitsu, Professor, Graduate School of Pharmaceutical Sciences, Kyushu University Japanese hospitals are currently bearing most of the expenses required for meeting biosafety regulations associated with gene therapy Zolgensma (onasemnogene abeparvovec) due to an extremely low reimbursement fee, an academic...read more